Podcasts about medpage today

It's In the News - a look at the top diabetes headlines and stories happening now. Our top stories: More information about type 1 and COVID, including the vaccine, why is the latest GLP-1 medication, not yet FDA approved, showing up all over the place, what table sugar and vinegar could mean for drug costs, a new inhaled insulin study and much more  I'll see you at Friends for Life next week. Come find me at Table T18 Learn more about our in-person events here: https://diabetes-connections.com/events/ Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Transcript & links:    Okay.. our top story this week: XX A large Swedish study found that the increased risk of being diagnosed with type 1 diabetes after COVID-19 infection is mostly limited to the first 30 days after infection and does not continue long term. Researchers followed nearly the entire Swedish population under age 80 from 2020 through 2023 and found that while SARS-CoV-2 infection was linked to a temporary rise in new type 1 diabetes diagnoses, the risk declined over time. The study also found no evidence that COVID-19 vaccination increases the long-term risk of developing type 1 diabetes. Vaccination did not significantly change the relationship between COVID-19 infection and diabetes risk, and any small increase in diagnoses seen among adults shortly after a first vaccine dose was not seen after later doses or during longer follow-up. The researchers concluded that their findings do not support changing current COVID-19 vaccination recommendations because of concerns about type 1 diabetes risk. https://www.infectiousdiseaseadvisor.com/news/covid19-infection-may-increase-short-term-type-1-diabetes-risk/ XX Two new studies are challenging the traditional view that type 1 diabetes develops solely because the immune system attacks insulin-producing beta cells. Researchers from Indiana University found evidence that beta cells themselves may play an active role in determining whether they survive or succumb to the stresses that lead to type 1 diabetes. In the first study, scientists discovered that some healthy human beta cells can quickly activate an antiviral defense system when exposed to interferon-alpha, an immune signal often produced during viral infections. This response relies on molecules called reactive oxygen species (ROS), which are usually associated with cell damage but, in this case, appeared to help switch on protective antiviral genes. Researchers found this defense program in healthy cells and in people at risk for type 1 diabetes, but not in beta cells from people who already had the disease. The findings suggest that losing this built-in defense mechanism may make beta cells more vulnerable during the development of type 1 diabetes. The second study focused on autophagy, the process cells use to recycle damaged or worn-out components. Using a new imaging technique, researchers observed that beta cells in a mouse model of type 1 diabetes showed defects in autophagy before blood sugar levels began to rise and even before a full immune attack was underway. This suggests that problems inside the beta cells may occur early in the disease process rather than being caused entirely by the immune system. Together, the studies point to a more complex picture of type 1 diabetes. While they do not show that beta-cell defects cause the disease, they suggest that differences in how beta cells respond to stress, viral signals, and cellular damage may influence who develops type 1 diabetes and how the disease progresses. https://medicalxpress.com/news/2026-06-beta-cells-players-diabetes.html XX Researchers have created the most detailed map yet of how the human pancreas develops during childhood, offering new clues about why children are especially vulnerable to developing diabetes. The study, published in Nature Communications, examined pancreatic tissue from 123 children without diabetes, ranging from newborns through age 10. Using advanced imaging techniques, scientists tracked how insulin-producing islet cells grow and mature during the first decade of life. The researchers found that pancreas size varies dramatically at birth, with some infants having pancreases nearly four times larger than others. They also discovered that insulin-producing beta cells grow more slowly after birth than previously thought, suggesting that much of a person's lifelong beta cell capacity may be established before birth and during early childhood. Other findings showed that insulin-producing cells mature earlier than glucagon-producing cells and that new hormone-producing cells may continue to form after birth. The researchers hope this new understanding of pancreas development will help scientists identify diabetes risk earlier and develop better strategies for prevention and treatment in children. https://news.vumc.org/2026/06/29/unlocking-diabetes-secrets-pediatric-organ-donors-help-map-a-path-to-a-cure-and-prevention/   XX At the American Diabetes Association annual meeting, 2-year results from the SUPPRESS-EARLY trial showed that initiating tirzepatide (Mounjaro, Zepbound) early in the course of type 2 diabetes led to substantially higher rates of near-normal glycemic control and also led to broader metabolic improvements compared with intensive conventional therapy.   In this MedPage Today video, investigator Stefano Del Prato, MD, of the University of Pisa in Italy, discusses the findings.     Following is a transcript of his remarks:   What happened is that in the tirzepatide-treated arm, 85% of the population at the end of the second year was on the maximum dose of tirzepatide 15 mg. And then the remaining 15 with the different doses.   Interestingly, in the population that had been treated with the intensive conventional approach, 85% of them ended up to have, on top of metformin, a GLP-1 receptor agonist, mainly represented by subcutaneous semaglutide [Ozempic, Wegovy], 60+%, another 15% on oral semaglutide [Rybelsus], and the remaining on dulaglutide [Trulicity].   And I have to say that maybe the recommendation to really push along the line to try to achieve and to strive to achieve [glycemic] control was successful in these individuals. Because the population that had been recruited in the study started off with a baseline A1C of 7.8% and it went down to 6.3% in the conventionally intensive treatment, which is not bad at all, on average is below the target of 6.5%.     However, when we look at the effect of tirzepatide, the final level of A1C at the end of the second year was 5.6%, which is on average below the upper limit of the normal range for A1C, 5.7%. This also translates into more people not only achieving normal glycemia, if we can define normal glycemia as A1C below 5.7%, greater than what we observed in conventionally treated individuals. So it was around three times more people achieving an A1C of 5.7%, in the range of around 65%, as compared to 28% with people on a conventional optimized treatment.   Now, this is not surprising knowing the potency of tirzepatide. But again, going back to the rationale of the design, can we change what is the natural history of the disease? This seems to be at least of interest and it's possibly changing the trajectory of the disease for glycemic control, as I mentioned, but also in terms of the body weight and waist circumference because both body weight and waist circumference went much lower with tirzepatide compared to the conventional treatment.   Tirzepatide also was associated with an improvement in the lipid profile, in particular with the LDL, triglycerides, and the triglyceride concentration and non-HDL cholesterol, and also with a statistically significantly lower systolic blood pressure with a numerical reduction in the diastolic blood pressure.   And also the other thing that probably will ... become more apparent with the study continuing is that the investigators were allowed to add on any other treatment ... needed to achieve their target. So tirzepatide was just metformin and tirzepatide. In the control group, there was already 10% of people who were receiving two drugs on top of the metformin.   So another potential result of the trial is that it's possible to achieve and maintain better glycemic or better metabolic control over the time without really needing to increase the number of medications in order to achieve that goal. And we know that type 2 diabetes is a progressive condition often requiring intensification of the treatment.   So these initial results really stand for a great opportunity with tirzepatide. Of course, we need to wait for the 4 years just to confirm that this is indeed the case, but the initial result seems to point along that line. https://www.medpagetoday.com/meetingcoverage/adavideopearls/121967 XX A study from the University of Virginia found that high blood pressure is extremely common among people with diabetes, even among those who believe their blood pressure is under control. Researchers measured blood pressure in 172 adults with type 1 or type 2 diabetes during routine eye clinic visits and found that only 8% had normal readings. About half had stage 2 hypertension, and more than 10% had blood pressure levels high enough to be considered a medical emergency. The study also revealed that many patients were unaware of how serious their blood pressure problems were. Among those who thought their hypertension was well controlled, more than half still had stage 2 hypertension. Nearly 60% of participants were advised to contact their primary care provider, and one patient required an emergency department referral. Most patients supported blood pressure screening during eye exams, leading researchers to suggest that routine blood pressure checks in ophthalmology clinics could help identify undiagnosed or poorly controlled hypertension before it leads to serious complications such as heart attack, stroke, or worsening diabetic eye disease. https://medicalxpress.com/news/2026-06-routine-eye-exams-reveal-stage.html XX What is going on with retatrutide? This is the next generation GLP-1 but it's not authorized outside of clinical trials. Big investigation by CBS shows retatrutide is for sale all over the internet, a phenomenon they say has no modern precedent. CBS News identified more than 120 websites selling or promoting retatrutide, including more than 50 clinics staffed by licensed medical professionals. After being contacted by CBS News, at least 21 clinics abruptly removed retatrutide from their websites or changed the language to state they don't offer it. Others defended prescribing it, saying they're confident enough in results from clinical trials sponsored by drugmaker Eli Lilly that they didn't need to wait for the FDA's independent, rigorous review. An FDA spokesperson said retatrutide "has not been found safe or effective for any condition," adding that it "cannot be manufactured or distributed except for investigational use." The Justice Department is prosecuting two cases – in Utah and Florida – involving the sale and prescription of retatrutide. But the first line of enforcement is often at the state level. Ohio's Board of Pharmacy has taken action against several pharmacies and clinics providing retatrutide, and just last month, Alabama's Medical Board warned physicians against prescribing research-grade medications. The FDA has sent 14 warning letters to companies that have advertised retatrutide since 2024. Of these, at least six have continued to offer it online, including a business called Pink Pony Peptides. A TikTok account associated with the firm responded to the warning in April by taunting the FDA, boasting that the business "just had the best 24 hours ever." In May, Eli Lilly announced that participants in a large clinical trial taking the highest dose of retatrutide lost an average of 28% of their body weight over 80 weeks. Side effects – including nausea, diarrhea, constipation and vomiting – were comparable to similar therapies, the company said. "Anyone purporting to sell retatrutide to consumers is breaking the law," an Eli Lilly spokesperson said https://www.cbsnews.com/projects/2026/experimental-weight-loss-drug/ XX Pioneering research has developed a new way of creating carbohydrate-based medicines, which could ultimately replace costly drugs for common health conditions, using two cheap basic ingredients – table sugar and vinegar. These medications include SGLT2 inhibitors, widely prescribed drugs used to treat type 2 diabetes, heart failure and chronic kidney disease. Co-lead author Professor Phil Baran, Dr. Richard A. Lerner Endowed Chair at Scripps Research, in San Diego, California, said: "The point of this is to show that anyone in a garage can make an SGLT2 inhibitor with reagents that are widely available. We have not patented this method, so we welcome any generic drug company – or anyone else – who wants to use it to help bring costs down for patients." https://www.newswise.com/articles/new-study-shows-table-sugar-could-hold-a-cheaper-quicker-key-to-making-vital-drugs-for-diabetes-heart-failure-and-chronic-kidney-disease XX England and Wales approve teplizumab to slow progression of T1D. At the moment, the Scottish Medicines Consortium does not have an appraisal of Tzield on the go, so, there is likely to be a disparity in access within the UK for the time being. In Northern Ireland, access will depend on a review and adoption of NICE guidance.  Sanofi is expecting to see an uptick in momentum thanks to two subsequent FDA approvals, one in children as young as one with stage 2 T1D, and a second to delay the decline in endogenous insulin production in children aged eight to 17 years recently diagnosed with stage 3 T1D. btw you might here more people referring to stage 4 diabetes. They've added that to include people diagnosed with type 1 who've been on insulin for a longer period of time – basically long enough to not be eligible for the current guidelines for Tzield. https://www.bbc.com/news/articles/ce8mzd94r76oXX XX Obesity Association, a division of the American Diabetes Association® (the association), announced the next section in the Standards of Care in Overweight and Obesity, "Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults," published in Diabetes, Obesity, and CardioMetabolic CARE® and BMJ Open Diabetes Research & Care.  Key highlights of the guidance: Early screening: Annual BMI screening with emphasis on tracking weight trends to identify risk earlier, including a longitudinal life-event weight graph tool for standardized assessment. Enhanced diagnosis: Combines BMI with waist measurements and population-specific thresholds to improve accuracy. Notably, the guidelines recommend that BMI in the overweight range together with central adiposity measurements warrant a formal obesity diagnosis. Comprehensive evaluation: Holistic assessment including medical, behavioral, and social factors. Offers a fully integrated obesity diagnostic algorithm. Risk stratification: Use of tools like the Edmonton Obesity Staging System to guide care. Chronic care approach: Ongoing monitoring and follow-up to support long-term management. Reducing bias: Promotes person-centered, non-stigmatizing care and system-level improvements at the clinical workflow level and encourages screening for prior weight bias/stigma experiences. https://www.prnewswire.com/news-releases/new-standards-of-care-in-overweight-and-obesity-section-screening-diagnosis-evaluation-and-staging-of-obesity-in-adults-302809670.html XX Dexcom (Nadsaq:DXCM) today announced the launch of its fully reimagined Stelo over-the-counter (OTC) sensor app experience. San Diego-based Dexcom plans to formally begin the new app rollout in July for Apple iPhone and Android users in the U.S. Dexcom said its reimagined app aims to make glucose insights easier to understand and act on. It hopes to help build awareness of how food, activity, sleep and stress influence overall wellbeing.   The company also reiterated plans to launch Stelo internationally. It expects to bring the sensor to the UK, Australia, New Zealand and South Korea later this year, continuing into 2027. https://www.drugdeliverybusiness.com/dexcom-launches-enhanced-stelo-app/ XX MannKind Corporation recently announced it received a grant from Breakthrough T1D to support the INHALE-1 clinical study of Afrezza, its ultra rapid-acting inhaled insulin, in newly diagnosed pediatric type 1 diabetes patients aged 10 to under 18 years. This external funding for a trial focused on early use of Afrezza in children highlights growing third-party support for inhaled insulin in pediatric diabetes care. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mnkd/mannkind/news/afrezza-pediatric-trial-grant-might-change-the-case-for-inve XX Alexander Zverev heads into Wimbledon with plenty of momentum. The French Open champion returns to the All England Club looking to build on his first Grand Slam title and gain ground on Carlos Alcaraz in the race for the No. 2 spot in the ATP rankings. Zverev has an opportunity to make up points quickly after a first-round exit at Wimbledon last year. But his final tune-up before Wimbledon came with an unexpected challenge. During his semifinal loss to Taylor Fritz at the Halle Open, Zverev said a malfunctioning glucose sensor led to serious diabetes management issues on court. The sensor incorrectly showed his blood sugar was high when it was actually low, causing him to take more insulin than needed. "I had huge problems with the sugar because the sensor I use gave me a completely incorrect reading," Zverev said after the match. "During the match, or rather during the first 45 minutes, I had to consume about 350 grams of sugar. I felt absolutely terrible." Despite feeling unwell, Zverev pushed the match to three sets before falling 6-7(4), 6-4, 7-5 to Fritz. He credited his opponent with playing the better match and said the diabetes-related issue was not an excuse for the result. Zverev, who was diagnosed with type 1 diabetes at age 4, uses Medtronic diabetes technology to help manage his glucose levels while competing on the ATP Tour. He said the sensor error was the first major problem he has experienced after nearly a decade of using the technology. The German said the incident should not affect his Wimbledon preparations. With the sensor issue behind him, Zverev will begin his Wimbledon campaign focused on adding another strong result to what has already been a breakthrough season.   https://www.reuters.com/sports/tennis/zverev-says-glucose-sensor-malfunction-affected-halle-semi-final-loss-fritz-2026-06-21/

Listen as hosts Tanner, John and Andy discuss their take on a recently published article in MedPage Today calling for the renaming of the Emergency Department and Emergency Medicine. Don't forget we are the official podcast of the American College of Osteopathic Emergency Physicians. Visit acoep.org today to learn more about an upcoming conference and how you can see your favorite EM Podcast LIVE and in person.

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss how public health groups across the country are monitoring infectious disease threats during the World Cup, another clash between physicians and private equity, and behind-the-scenes on how we broke news about ADA kicking out diabetes researchers from their annual conference and the chaos that ensued after. Episode produced and hosted by Rachael Robertson. Sound engineering by

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss what you need to know about a new rule politicizing grants, lessons from the 2014 Ebola care teams, and updates on the hantavirus situation. Episode produced and hosted by Rachael Robertson. Sound engineering by

Part 1:We talk with Lynne Stuart Parramore, cultural historian, essayist, and Research Analyst at the Institute for New Economic Thinking.We discuss the consequences of AI installations and data centers. We examine the power and water requirements for these centers, and what the effects will be on people who live near them. In addition, we look at the costs associated with them. Who is getting rich from this technology? Who is losing out?Part 2 We talk with Joyce Frieden, who oversees the coverage that Medpage Today provides about Washington's Health Policy.We learn that policies about enrolling seniors into Medicare Advantage programs are changing. Under a new proposed policy, seniors will be auto-enrolled, with few options to opt out or leave enrollment. There are many disadvantages in these types of plans, and we discuss them.WNHNFM.ORG  productionMusic: "That's how every empire falls," John Prine

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss what you need to know about the hantavirus situation, how CMS is considering auto-enrolling some patients in MA, and new research on Mel Gibson's ivermectin influence. Episode produced and hosted by Rachael Robertson. Sound engineering by

Photo by Vitalii Pavlyshynets on Unsplash Secretary of Health and Human Services, Robert F. Kennedy, Jr., continues to push forward his Make America Healthy Again or MAHA agenda that has been both hailed for its attention to things like nutrition and chemical exposures, and criticized for what some see as its inadequacies in being evidence based and detracting from the importance of protecting the public against infectious diseases. On April 15, 2026, MedPage Today published a commentary on whether Kennedy’s approach to MAHA is more political marketing than evidence-based health guidance. The commentary was written by Adam Brown, MD, Contributing Writer to MedPage Today, a board-certified emergency medicine and lifestyle medicine physician, and founder of ABIG Health that advises healthcare organizations on strategy and innovation. He is a past President of Emergency Medicine at Envision Healthcare and currently a professor at UNC Chapel Hill at Kenan-Flagler Business School and a visiting professor of business at ESCP Business School in London and Paris. HealthCetera producer and host Diana J. Mason, PhD, RN, talked with Dr. Brown about his views on MAHA and its promotion by Kennedy. This interview first aired on HealthCetera in the Catskills on April 22, 20026. The post A Commentary on Make America Healthy Again appeared first on HealthCetera.

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss what you need to know about RFK Jr.'s "hearingpalooza," how the majority of articles published in a guest-edited BMJ journal edition were retracted, and new research on "superretractors." Episode produced and hosted by Rachael Robertson. Sound engineering by

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss how “The Pitt” has handled the pervasive "ortho bro" stereotype and what doctors want to see next season, how some states are working to make it easier for foreign-trained doctors to practice in the U.S, and healthcare professionals' vaccination rates. Episode produced and hosted by Rachael Robertson. Sound engineering by

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss how CMS Administrator Mehmet Oz, MD, MBA is handling Medicare and Medicaid fraud, Match Day 2026 trends, and a rare disease that may be popping up tied to increasing vaccine hesitancy. Episode produced and hosted by Rachael Robertson. Sound engineering by

What makes The Pitt feel different from other medical dramas? In this 53-minute MedPage Today special dispatch, Jeremy Faust, MD, speaks with Joe Sachs, MD, emergency physician and executive producer of the hit series, about how the show balances clinical accuracy with storytelling, and why it's resonating with both clinicians and the public. From meticulous on-set medical consulting to storylines drawn from real patient experiences, Sachs explains how The Pitt is not just entertainment — but, increasingly, a force in medical education and public health awareness.

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss a battle in Oregon over local versus corporate emergency room ownership, what ob/gyns have to say about so-called trimester zero, and which public health figures the public actually trusts. Episode produced and hosted by Rachael Robertson. Sound engineering by

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss the revolving door leadership at NIH's Institutes and Centers, UnitedHealthcare's controversial new Medicare Advantage policy, and a bill that would erase two decades worth of certain types of state nursing board discipline. Episode produced and hosted by Rachael Robertson. Sound engineering by

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss the killing of ICU nurse Alex Pretti, what doctors think about ChatGPT Health, and RFK Jr.'s claims about fermented food and weight loss. Episode produced and hosted by Rachael Robertson. Sound engineering by

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss changes to the childhood immunization schedule, the controversial new dietary guidelines', and a MedPage project tracking the spread of measles. Episode produced and hosted by Rachael Robertson. Sound engineering by

Claim your complimentary gift of my exclusive mini weight care guide today!Link: Weight Care Guide — Dr. Francavilla Show (thedrfrancavillashow.com)Ever wondered what's really changing the game in weight loss treatments? Well, oral Wegovy might be it. Unlike other GLP-1 medications that require weekly injections, this is the first long-term weight-loss pill in its class. For many people, taking a daily tablet just feels way more doable—it's flexible, lowers mental barriers, and makes managing weight something that can actually fit into everyday life.In this episode, my guest is Joseph “Joe” Zucchi, a physician assistant and personal trainer with over a decade of experience in obesity medicine. He leads a multidisciplinary team in Salem, New Hampshire, helping patients achieve sustainable weight loss through a mix of fitness, nutrition, and medical care. Joe has been recognized for his work—leading his center to win awards, writing for outlets like the Wall Street Journal, MedPage Today, Healthline, and Doximity, and advocating for patient access to treatments like Zepbound. His insights make it clear that oral Wegovy isn't just another pill—it's part of a thoughtfully designed, patient-centered approach to obesity care.In this episode, we break down everything you need to know, including GLP-1 medications in simple terms, the future of oral Wegovy, what counts as success on the pill, side effects to expect, the technology behind it, how to take it properly, safely transitioning between pill and injection, who benefits most (and who should avoid it), and cost, coverage, and what to expect in 2026. If you've been curious about how oral Wegovy works and whether it could be right for you, this episode walks through it all in practical, real-world terms.Connect with Mr. Zucchi:Linkedin: Joseph Zucchi, PA-CX: JPZfitness Instagram: transitionweightlossConnect with me:Instagram: doctorfrancavillaFacebook: Help Your Patients Lose Weight with Dr. FrancavillaWebsite: Dr. Francavilla ShowYoutube: The Doctor Francavilla ShowGLP Strong: glpstrong.com

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss a conspiracy theory about the origins of Lyme disease, ob/gyns' reactions to 'wild pregnancies' and 'freebirths', and the struggles facing a CMS Diabetes Prevention Program. Episode produced and hosted by Rachael Robertson. Sound engineering by

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss a scoop on new CDC leadership, the different facets of the MAHA empire, and how some see echoes of eugenics in MAHA. Episode produced and hosted by Rachael Robertson. Sound engineering by

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss how the decision to remove the black box warning on menopause hormone therapy products, how and why some GLP-1s will now be covered by Medicare, and new research on butt breathing. Episode produced and hosted by Rachael Robertson. Sound engineering by

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss how the reductions-in-force at CDC and the surrounding chaos, FDA's crackdown on the unapproved weight-loss drug retatrutide, and which hospitals are performing the most, unnecessary spine surgeries. Episode produced and hosted by Rachael Robertson. Sound engineering by

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss how the government shutdown may affect healthcare, the debate on whether physician paid expert witnesses can ever be truly impartial, and what we know about HHS Secretary Robert F. Kennedy Jr.'s CDC contact, Dr. William Thompson. Episode produced and hosted by Rachael Robertson. Sound engineering by

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss the latest RFK Jr. news, Florida's announcement it would end vaccine mandates, and the top research from the European Society of Cardiologyannual meeting. Episode produced and hosted by Rachael Robertson. Sound engineering by

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss how the public health community is responding to the shooting at CDC, why nutrition and obesity experts are worried about upcoming dietary guidelines, and how an executive order putting political appointees in charge of reviewing grants from federal agencies will impact medical research. Episode produced and hosted by Rachael Robertson. Sound engineering by

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss an FDA official's abrupt exit and the future of USPSTF, a major publishing slowdown at MMWR, and why FDA's so-called 'expert panels' are raising red flags. Episode produced and hosted by Rachael Robertson. Sound engineering by

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss how the federal government has been targeting gender-affirming care for youth, which states have passed laws making ivermectin available over-the-counter (OTC), and highlight some under-the-radar provisions in the so-called "Big Beautiful Bill" that haven't gotten much media attention. Episode produced and hosted by Rachael Robertson. Sound engineering by

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss the first day of the

Welcome to The Mental Breakdown and Psychreg Podcast! Today, Dr. Berney and Dr. Marshall discuss the way self-diagnosing interferes with identity development in teenagers. Read the articles from Medpage Today here and from Johns Hopkins Medical here. You can now follow Dr. Marshall on twitter, as well! Dr. Berney and Dr. Marshall are happy to announce the release of their new parenting e-book, Handbook for Raising an Emotionally Healthy Child Part 2: Attention. You can get your copy from Amazon here. We hope that you will join us each morning so that we can help you make your day the best it can be! See you tomorrow. Become a patron and support our work at http://www.Patreon.com/thementalbreakdown. Visit Psychreg for blog posts covering a variety of topics within the fields of mental health and psychology. The Parenting Your ADHD Child course is now on YouTube! Check it out at the Paedeia YouTube Channel. The Handbook for Raising an Emotionally Health Child Part 1: Behavior Management is now available on kindle! Get your copy today! The Elimination Diet Manual is now available on kindle and nook! Get your copy today! Follow us on Twitter and Facebook and subscribe to our YouTube Channels, Paedeia and The Mental Breakdown. Please leave us a review on iTunes so that others might find our podcast and join in on the conversation!

Welcome to The Mental Breakdown and Psychreg Podcast! Today, Dr. Berney and Dr. Marshall discuss the specific concerns that arise when teens self-diagnose. Read the articles from Medpage Today here and from Johns Hopkins Medical here. You can now follow Dr. Marshall on twitter, as well! Dr. Berney and Dr. Marshall are happy to announce the release of their new parenting e-book, Handbook for Raising an Emotionally Healthy Child Part 2: Attention. You can get your copy from Amazon here. We hope that you will join us each morning so that we can help you make your day the best it can be! See you tomorrow. Become a patron and support our work at http://www.Patreon.com/thementalbreakdown. Visit Psychreg for blog posts covering a variety of topics within the fields of mental health and psychology. The Parenting Your ADHD Child course is now on YouTube! Check it out at the Paedeia YouTube Channel. The Handbook for Raising an Emotionally Health Child Part 1: Behavior Management is now available on kindle! Get your copy today! The Elimination Diet Manual is now available on kindle and nook! Get your copy today! Follow us on Twitter and Facebook and subscribe to our YouTube Channels, Paedeia and The Mental Breakdown. Please leave us a review on iTunes so that others might find our podcast and join in on the conversation!

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss the first FDA-approved

Listen as Gaining Health host, Karli Burridge, reflects on the OMA Annual Conference with Sam and Joe!Petition to keep Zepbound on formulary:  https://www.change.org/p/stop-cvs-caremark-s-zepbound-ban-restore-coverage-of-the-superior-obesity-medicationSandra Christensen is board-certified as a family nurse practitioner and holds the Certificate of Advanced Education in Obesity Medicine from the Obesity Medicine Association. She is the founder and Chief Clinical Officer of Integrative Medical Weight Management in Seattle, Washington, and has specialized in obesity management since 2005. She is a Master Fellow of the Obesity Medicine Association and a Fellow of the American Association of Nurse Practitioners. She serves on the Board of Trustees for the Obesity Medicine Association and is the President of the Washington Obesity Society.  She authored the book, “A Clinician's Guide to Discussing Obesity with Patients” published by Springer, and was named the 2022 Obesity Medicine Association Clinician of the Year.The Washington Obesity SocietyIntegrative Medical Weight Managementhttps://www.linkedin.com/in/sandra-christensen/Joseph Zucchi (pronounced Zoo-key) is a board-certified Physician Assistant and Personal Trainer who serves as the Clinical Supervisor of Transition Medical Weight Loss in Salem, New Hampshire. With over a decade of experience in obesity medicine, Joe leads a multidisciplinary team dedicated to helping patients achieve sustainable weight loss and improved health. He has worked with over 2,000 patients to collectively lose more than 40,000 pounds. Joe integrates fitness, nutrition, and medical interventions to provide comprehensive, patient-centered care.  His work has been recognized through multiple accolades, including leading Transition Medical Weight Loss to win awards for best weight loss center in NH. He has written articles and has shared his expertise on obesity care and weight-loss treatments in outlets like the Wall Street Journal, MedPage Today, Healthline, and Doximity. Joe also is a speaker for Eli Lilly and educates other providers about Zepbound and obesity medicine. https://www.linkedin.com/in/josephzucchi/https://x.com/JPZfitnesshttps://transitionsalem.com/Support the showThe Gaining Health Podcast will release a new episode monthly, every second or third Wednesday of the month. Episodes including interviews with obesity experts as well as scientific updates and new guidelines for the management of obesity.If you're a clinician or organization looking to start or optimize an obesity management program, and you want additional support and resources, check out the Gaining Health website! We offer a Roadmap to starting an obesity program or practice, pre-recorded Master Classes, digital resources including patient education materials and office forms, and much more! Check out our resources on our Gaining Health Shop! If you are loving this podcast, please consider supporting us on Patreon

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss our editor-in-chief Jeremy Faust's

Send us a textHelp me improve the podcast by answering a few questions here.In this episode of Live Long and Well, I'm joined by Dr. Anthony Pearson, a board-certified cardiologist known for his evidence-based yet refreshingly skeptical take on mainstream cardiac care. Together, we explore the nuanced science behind heart health and how you can make smarter decisions to protect your cardiovascular system—starting today.We open by recognizing that heart disease remains the leading cause of death for both men and women. While many of the six pillars of longevity—from exercise to stress reduction—play protective roles, today's episode zooms in on two powerful, sometimes polarizing topics: the role of diet in heart health and the value of coronary artery calcium (CAC) scans.Dr. Pearson shares how a personal brunch conversation with his wife challenged decades of low-fat dietary dogma, prompting his transformation into the "Skeptical Cardiologist." Here is a summary showing that dairy won't increase risk of cardiovascular disease. He recounts the We dive into the broader saturated fat debate, highlighting how different fat sources have varied effects on cholesterol and cardiovascular risk. While dairy fats may be benign or even beneficial, others—particularly those consumed in excess on paleo or keto diets—can raise LDL cholesterol substantially. Dr. Pearson discusses the Keto-CAD Study, which found that even lean, low-risk keto followers may build up arterial plaque if their LDL levels skyrocket.The conversation then shifts to the calcium heart or CAC scan, a non-invasive $100 screening test that quantifies calcified coronary artery plaque via CT imaging. While traditional risk calculators like the pooled cohort equations often fall short, CAC scoring offers a personalized look at actual plaque burden—critical since many heart attacks occur in people not flagged as high-risk. As Dr. Pearson explains, a high score doesn't mean you will need surgery. Instead, it's typically a cue for lifestyle and medication adjustments, not invasive procedures. He references the ISCHEMIA Trial, which found no benefit from stenting stable, asymptomatic patients over optimized medical therapy.We close with practical advice: talk to your doctor, especially if you have a family history or fall in that “borderline risk” zone where a CAC score might influence your care plan. And yes, it should be okay to keep enjoying that butter—as long as you're informed and mindful and don't overdue it.Takeaways: Full-fat dairy is not the enemy—it may even be heart-protective. If your LDL skyrockets on keto, that's a red flag worth addressing. CAC scans can personalize your prevention plan and offer peace of mind or a critical nudge toward action. Want more clarity on your own heart health journey? Talk with your doctor about whether a calcium scan makes sense for you and explore Dr. Pearson's writings on The Skeptical Cardiologist and MedPage Today.

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss letters the

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss the fallout from major

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss the disturbing story of a hospital

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss the deluge of healthcare news updates out of Washington from the past month. Episode produced and hosted by Rachael Robertson. Sound engineering by

How is Trump's executive order redefining the language permissible in scientific research, and what does it mean for academic freedom? Today, we examine the complexities surrounding scientific research under shifting political landscapes with Ivan Oransky, a seasoned medical journalist and co-founder of Retraction Watch. Oransky discusses the implications of President Trump's executive orders and how it has sent ripples throughout the scientific community, causing researchers to reconsider their work amidst existential uncertainties. Oransky explores the nuanced relationship between government funding and scientific inquiry. This episode unpacks the historical precedents of government involvement in research, tracing back to the 1940s, and examines the mounting challenges faced by scientists under the recent policy changes. Oransky provides a critical analysis of how such directives potentially stifle open inquiry and drive talented researchers away, ultimately impacting the future landscape of scientific discovery. In This Episode:Implications of Trump's executive orders on scientific researchHistorical context of government funding in scientific researchThe impact of political climates on scientific inquiry and transparencyChallenges of anticipatory obedience within research communitiesIvan Oransky's insights on sustaining open and rigorous scientific dialogue About Ivan:Ivan Oransky, MD, is the co-founder of Retraction Watch, the Editor in Chief of The Transmitter, and a Distinguished Journalist in Residence at New York University's Carter Journalism Institute, where he teaches medical journalism. He has held leadership positions at Medscape, MedPage Today, Reuters Health, Scientific American, and The Scientist. A former president of the Association of Health Care Journalists from 2017 to 2021, Oransky earned his bachelor's degree from Harvard and an MD from NYU School of Medicine. His contributions to biomedical communication have earned him accolades, including the John P. McGovern Award and commendation from the John Maddox Prize judges for his work at Retraction Watch. Read HXA's newsletter Free the Inquiry: https://heterodoxacademy.substack.com/Follow Ivan on X: https://x.com/ivanoransky  Follow Heterodox Academy on:Twitter: https://bit.ly/3Fax5DyFacebook: https://bit.ly/3PMYxfwLinkedIn: https://bit.ly/48IYeuJInstagram: https://bit.ly/46HKfUgSubstack: https://bit.ly/48IhjNF

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss the deluge of healthcare news updates from the first few weeks of the second Trump presidency. Episode produced and hosted by Rachael Robertson. Sound engineering by

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss the growing 'medical freedom' movement, another way that private equity harms patients, and the latest updates on the USMLE cheating scandal . Episode produced and hosted by Rachael Robertson. Sound engineering by Jennifer Henderson, Kristina Fiore, and Rachael Robertson.

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss how the murder of United Healthcare's CEO raised questions about the risks healthcare leadership faces, RFK Jr. health-related conspiracies, and 'gold card' laws. Episode produced and hosted by Rachael Robertson. Sound engineering by Michael DePeau-Wilson, Joyce Frieden, and Shannon Firth.

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss what happens to healthcare under Trump, including what actions he'll take and how he'll handle the Federal Trade Commission. Episode produced and hosted by Rachael Robertson. Sound engineering by Joyce Frieden and Shannon Firth.

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discussallegations of a toxic work environment at the University of Virginia, new recommendations for additional COVID vaccines for older adults, and how some medical schools are giving credit for parenting and caregiving'. Episode produced and hosted by Rachael Robertson. Sound engineering by

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discussa medical education rundown, the first doctor of chiropractic program, and why MedPAC is questioning the value of 'extra benefits'. Episode produced and hosted by Rachael Robertson. Sound engineering by Greg Laub. Reporting by Rachael Robertson, Sophie Putka, and Cheryl Clark.

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discussa new COVID variant, why the FDA is concerned about amniotic fluid in eyedrops, conversations happening in California about certified registered nurse anesthetists' scope of practice. Episode produced and hosted by Rachael Robertson. Sound engineering by Greg Laub. Reporting by Kristina Fiore, Sophie Putka, and Jennifer Henderson.

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss how Tennessee is trying to fill their physician shortage and why they're facing some hurdles. Plus, we dive into the question: how addictive is ketamine, the drug that killed Matthew Perry ? And lastly, a new off-Broadway musical about antimicrobial resistance. Episode produced and hosted by Rachael Robertson. Sound engineering by Greg Laub. Reporting by Cheryl Clark, Sophie Putka, and Rachael Robertson.

In this episode, host Jeremy Dyer of the Freedom Point Podcast interviews Dr. Christopher H. Loo, MD-PhD, a surgeon turned serial entrepreneur, investor, author, consultant, executive coach, and keynote speaker. Dr. Loo shares his remarkable journey from achieving financial independence at the age of 29 to retiring early at 38. Discover how Dr. Loo managed to balance his time and clinical responsibilities to produce optimal outcomes and attain financial freedom. Learn about his multiple passive income strategies and the importance of financial literacy among physicians. Dr. Loo also discusses his travels, his consulting company, and the inspiration behind his four Amazon bestselling books, including "How I Quit My Lucrative Medical Career and Achieved Financial Freedom Using Real Estate." Tune in as we delve into Dr. Loo's contributions to notable platforms like KevinMD, Doximity, MedPage Today, and his role as the host of the Financial Freedom for Physicians Podcast. Gain valuable insights from his experiences and strategies, and find out how you can join his thriving community of over 1000+ physicians on their journey to financial independence. Note: reproduced with permission. Visit: https://youtu.be/iz79hbLn9Eg?si=TqFq6Tyq-W-OqYhK to view the original source link. Disclaimer: Not advice. Educational purposes only. Not an endorsement for or against. Results not vetted. Views of the guests do not represent those of the host or show. Do your due diligence. Click here to join PodMatch (the "AirBNB" of Podcasting): https://www.joinpodmatch.com/drchrisloomdphd We couldn't do it without the support of our listeners. To help support the show: CashApp- https://cash.app/$drchrisloomdphd Venmo- https://account.venmo.com/u/Chris-Loo-4 Buy Me a Coffee- https://www.buymeacoffee.com/chrisJx Click here to schedule a 1-on-1 private coaching call: https://www.drchrisloomdphd.com/book-online Click here to purchase my books on Amazon: https://amzn.to/2PaQn4p Follow our YouTube channel: https://www.youtube.com/chL1357 Follow us on Twitter: https://www.twitter.com/drchrisloomdphd Follow us on Instagram: https://www.instagram.com/thereal_drchrisloo Follow us on Threads: https://www.threads.net/@thereal_drchrisloo Follow us on TikTok: https://www.tiktok.com/@drchrisloomddphd Follow the podcast on Spotify: https://open.spotify.com/show/3NkM6US7cjsiAYTBjWGdx6?si=1da9d0a17be14d18 Subscribe to our Substack newsletter: https://substack.com/@drchrisloomdphd1 Subscribe to our Medium newsletter: https://medium.com/@drchrisloomdphd Subscribe to our email newsletter: ⁠https://financial-freedom-for-physicians.ck.page/b4622e816d⁠ Subscribe to our LinkedIn newsletter: https://www.linkedin.com/build-relation/newsletter-follow?entityUrn=6992935013231071233 Join our Patreon Community: https://www.patreon.com/user?u=87512799 Join our Spotify Community: ⁠https://podcasters.spotify.com/pod/show/christopher-loo/subscribe⁠ Thank you to our advertisers on Spotify. Financial Freedom for Physicians, Copyright 2024

Much in our modern lives depends on GPS. But the United States’ GPS system is getting old and hasn’t kept up with international competition. We’ll get into how this leaves the U.S. vulnerable to national security threats. And, new data shows that as abortion protections have eroded across the country, more young women have been getting sterilized. Plus, one nonprofit’s work to give kids who’ve aged out of foster care a bona fide college move-in experience, and a women’s soccer stadium’s surprise success story. Here’s everything we talked about today: “Why GPS Is Under Attack” from The New York Times “Rate of Young Women Getting Sterilized Doubled After Roe Was Overturned” from MedPage Today “Move-In Day Mafia Helps Kids From Foster Care Settle In College” from Black Enterprise “No One Wanted to Finance Their Stadium. Now Every Game Is a Sellout.” from The Wall Street Journal We love to hear from you. Send your questions and comments to makemesmart@marketplace.org or leave us a voicemail at 508-U-B-SMART.

Much in our modern lives depends on GPS. But the United States’ GPS system is getting old and hasn’t kept up with international competition. We’ll get into how this leaves the U.S. vulnerable to national security threats. And, new data shows that as abortion protections have eroded across the country, more young women have been getting sterilized. Plus, one nonprofit’s work to give kids who’ve aged out of foster care a bona fide college move-in experience, and a women’s soccer stadium’s surprise success story. Here’s everything we talked about today: “Why GPS Is Under Attack” from The New York Times “Rate of Young Women Getting Sterilized Doubled After Roe Was Overturned” from MedPage Today “Move-In Day Mafia Helps Kids From Foster Care Settle In College” from Black Enterprise “No One Wanted to Finance Their Stadium. Now Every Game Is a Sellout.” from The Wall Street Journal We love to hear from you. Send your questions and comments to makemesmart@marketplace.org or leave us a voicemail at 508-U-B-SMART.

Much in our modern lives depends on GPS. But the United States’ GPS system is getting old and hasn’t kept up with international competition. We’ll get into how this leaves the U.S. vulnerable to national security threats. And, new data shows that as abortion protections have eroded across the country, more young women have been getting sterilized. Plus, one nonprofit’s work to give kids who’ve aged out of foster care a bona fide college move-in experience, and a women’s soccer stadium’s surprise success story. Here’s everything we talked about today: “Why GPS Is Under Attack” from The New York Times “Rate of Young Women Getting Sterilized Doubled After Roe Was Overturned” from MedPage Today “Move-In Day Mafia Helps Kids From Foster Care Settle In College” from Black Enterprise “No One Wanted to Finance Their Stadium. Now Every Game Is a Sellout.” from The Wall Street Journal We love to hear from you. Send your questions and comments to makemesmart@marketplace.org or leave us a voicemail at 508-U-B-SMART.